Project Jacaranda
Confidential summary for informational purposes only — not an offer or solicitation. Details provided to qualified parties upon request/NDA.
Company Profile
Specialized pharmaceutical company with advanced manufacturing and packing capabilities plus a robust in-house development portfolio.
Approved by US FDA, TGA and EU GMP, with repeat success across major international inspections.
Commercial model spans in-house products, contract manufacturing and institutional / tender supply.
Use of Funds
Expansion supports new cleanrooms, a sterile line, high-potency infrastructure and QC laboratory modernization. Commercial model spans in-house products, contract manufacturing and institutional / tender supply, with projected 2031 revenue of $40 million.
Transaction Overview
Seeking US $14 million strategic partnership to expand into higher-margin sterile manufacturing capabilities.
Expansion adds sterile injectables plus oral solid / liquid lines to support future scale-up.
Proceeds to fund WH2 cleanrooms, a new sterile line, high-potency infrastructure and QC lab modernization.